Antisense-mediated exon inclusion

21Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Exon skipping induced by gene mutations is a common mechanism responsible for many genetic diseases. A practical approach to correct the aberrant splicing of defective genes is to use antisense oligonucleotides (ASOs). The recognition of splice sites and the regulation of splicing involve multiple positive or negative cis-acting elements and trans-acting factors. Base-pairing of ASOs to a negative element in a targeted pre-mRNA blocks the binding of splicing repressors to this cis-element and/or disrupts an unfavorable secondary structure; as a result, the ASO restores exon inclusion. For example, we have recently shown that appropriate 2-O-(2-methoxyethyl) (MOE) phosphorothioate- modified ASOs can efficiently correct survival motor neuron 2 (SMN2) exon 7 splicing in a cell-free splicing assay, in cultured human cells-including patient fibroblasts-and in both peripheral tissues and the CNS of SMA mouse models. These ASOs are promising drug leads for SMA therapy. © 2012 Springer Science+Business Media, LLC.

Cite

CITATION STYLE

APA

Hua, Y., & Krainer, A. R. (2012). Antisense-mediated exon inclusion. Methods in Molecular Biology, 867, 307–323. https://doi.org/10.1007/978-1-61779-767-5_20

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free